The username/email didn't match the password, please try again!

Forgot your password?

The email you have inserted is not registered at Medicon Valley Online. If you wish to gain access to a specific organization profile please speak to one of the registered contacts of that organization. The registered contacts can usually be found on the profile page of that organization.

The email you have inserted is not in our database. Plese try again!

To add a compound to a pipeline your organisation needs to be registered as a biotech or pharmaceutical company at Medicon Valley Online. If your organisation is already registered please click on the Sign in button below. If you wish to register a new organisation, please click the Register button.

To add a service your organisation needs to be registered at Medicon Valley Online as a member of Medicon Valley Alliance and have paid the one time fee of 2300 EUR for the service section. If this has been accomplished please, just click the Sign in button below. If you want access to the services section or media about it please send your contact details to and we will get back to you.


(Uncheck if on a shared computer)
Forgot your password?
Create Account
Please enter your email address in the field below. Once submitted a message, with an authorization link, will be sent to this address so that you can set a new password for your account. You will have access to you account again in a couple of minutes. Thank you for your patience.
Medicon Valley Online
Drug Pipeline
Contract Services
Job Market
View all organisations

CytoVac A/S

Biotech Company / Biological Products

Member of Medicon Valley Alliance

description Description

CytoVac A/S is a research and clinical development company focused on cell-based personalized therapies, aiming to provide new possibilities for treatment of serious disease, in the area of oncology and other life threatening diseases. CytoVac is in collaboration with hospitals in Denmark performing Phase I and II clinical trials of products for treatment of Brain(GBM)-, Prostate- and Pancreas- cancer. CytoVac has established GMP-approved production facilities that are approved by the Danish Medicines Agency and as a centre for handling and manufacturing human Cell and Tissue-based products.

Drug Pipeline

compound ALECSAT [Internal project]

ALECSAT may be applied to many cancer forms if the tumors if express the relevant antigens. ALECSAT cells are directed towards wide range of antigens among them the Cancer Testes Antigen (CTA) which is a major group of cancer specific antigens that are expressed by numerous cancers. CytoVac’s clinical development program has so far focused on two different cancer forms - Prostate cancer and Glioblastoma brain cancer, and a clinical trial program has now also been initiated in Pancreatic cancer. The ALECSAT product that is used in these treatments is the same for all disease indications. These are disease areas with high unmet needs and significant market potential. ALECSAT treatment method can also potentially be applied to a number of other cancer types; future clinical trials will verify this. Two new clinical trials have been started in Pancreatic cancer (clinical phase I) and Glioblasoma (Clinical phase II) to support our clinical program.

Read more about ALECSAT go

Drug development

Therapeutical Area / Indication Pre-
Cancers and Other Neoplasms
primary Glioblastoma Pre-clinical Phase I Phase II Phase III Phase IV
Carcinoma, Pancreatic Ductal Pre-clinical Phase I Phase II Phase III Phase IV
Prostate cancer Pre-clinical Phase I Phase II Phase III Phase IV

Staff Top top

Martin R. Jensen
Martin R. Jensen
+45 45 57 22 45 (Office)
+45 26 37 33 80 (Mobile)

Contact Top top

CytoVac A/S
Tel: +45 45 57 22 45
Fax: +45 45 57 22 40

Venlighedsvej 6
©2010 Medicon Valley Online - Brought to you by Medicon Valley Alliance. All rights reserved.